FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology. Described is a group of inventions comprising an antibody or an antigen-binding fragment specifically binding to IL-21, a conjugate for inhibiting functional activity of IL-21 containing said antibody, a pharmaceutical composition for treating or preventing an autoimmune disease or graft-versus-host disease (GVHD) associated with IL-21, a method of treating or preventing an autoimmune disease or disorder in a subject, a method of determining expression levels of IL-21 and a method of treating or preventing a graft-versus-host reaction associated with IL-21. In one embodiment, the antibody comprises (a) CDR1, CDR2 and CDR3 of the VH region comprising DYWMH (SEQ ID NO: 7), TIDPSDNYTIYSQNFKG (SEQ ID NO: 8) replacing asparagine (N) glutamine (Q) in position 7 and YGFAMDY (SEQ ID NO: 9) respectively; and (b) CDR1, CDR2 and CDR3 of VL region comprising RASQDISNFLN (SEQ ID NO: 12), YTSRLHS (SEQ ID NO: 13) and QQGHTLPRT (SEQ ID NO: 14).
EFFECT: invention extends the range of products for binding with IL-21.
16 cl, 14 dwg, 7 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BINDING MOLECULES SPECIFIC TO IL-21 AND THEIR USE | 2015 |
|
RU2804456C1 |
| ANTI-KIT ANTIBODIES AND USES THEREOF | 2013 |
|
RU2681730C2 |
| ANTIBODIES AGAINST CXCR5, THEIR COMPOSITIONS AND USE | 2018 |
|
RU2798422C2 |
| ANTI-αvβ8 ANTIBODIES AND COMPOSITIONS AND THEIR USE | 2019 |
|
RU2812478C2 |
| BINDING MOLECULE SPECIFIC FOR HER3, AND THEIR APPLICATIONS | 2012 |
|
RU2620068C2 |
| CD3-BINDING DOMAIN | 2015 |
|
RU2742691C2 |
| ANTIBODIES AGAINST PD-1 AND THEIR USE | 2018 |
|
RU2788616C2 |
| HUMANISED ANTIBODIES TO OX40 AND METHODS FOR USE THEREOF | 2015 |
|
RU2709742C2 |
| ANTIBODIES AGAINST A5 REPRESENTATIVE OF 19 FAMILY WITH SIMILARITY OF SEQUENCES AND THEIR APPLICATION METHOD | 2019 |
|
RU2785436C2 |
| SPECIFIC LINKING AGENTS AGAINST B7-H1 | 2010 |
|
RU2571204C2 |
